TY - JOUR
T1 - Hepatocellular carcinoma in Olmsted County, Minnesota, 1976-2008
AU - Yang, Ju Dong
AU - Kim, Bohyun
AU - Sanderson, Schuyler O.
AU - St Sauver, Jennifer L.
AU - Yawn, Barbara P.
AU - Pedersen, Rachel A.
AU - Larson, Joseph J.
AU - Therneau, Terry M.
AU - Roberts, Lewis R.
AU - Kim, W. Ray
N1 - Funding Information:
Grant Support: This study was funded by grants DK84832 and DK34238 from the National Institute of Diabetes and Digestive and Kidney Diseases ; Rochester Epidemiology Project R01 AG034676 from the National Institute on Aging ; and Clinical and Translational Science Award UL1 RR024150 from the National Center for Research Resources , a component of the National Institutes of Health.
Funding Information:
Potential Competing Interests: Dr Roberts has indicated research grants from Bristol Myers Squibb and MDS Nordion .
PY - 2012/1
Y1 - 2012/1
N2 - Objective: To analyze longitudinal trends in the incidence, etiology, and treatment of hepatocellular carcinoma (HCC) in community residents in Olmsted County, Minnesota, and their survival. Patients and Methods: Olmsted County residents 20 years or older with HCC newly diagnosed from January 1, 1976, through December 31, 2008, were identified using a community-wide medical record linkage system (Rochester Epidemiology Project). The incidence rate of HCC was calculated by age and sex according to the 2000 US Census population. Temporal trends of HCC etiology, treatment, and patient survival were assessed. Results: The age- and sex-adjusted incidence rate for HCC in Olmsted County was 3.5 per 100,000 person-years for the first era (1976-1990), 3.8 per 100,000 for the second era (1991-2000), and 6.9 per 100,000 for the third era (2001-2008). Alcohol use was the most common risk factor in the first and second eras and chronic hepatitis C virus in the third. The proportion attributed to nonalcoholic fatty liver disease was small (5/47 [10.6%] in the third era). Because the proportion of patients receiving curative treatment increased over time, survival also improved, with a median survival time of 3, 6, and 9 months in the first, second, and third eras, respectively (P=.01). Conclusion: In this midwestern US community, the incidence of HCC has increased, primarily due to hepatitis C virus. Although there was a demonstrable improvement in the outcome of HCC in community residents over time, the overall prognosis remains poor.
AB - Objective: To analyze longitudinal trends in the incidence, etiology, and treatment of hepatocellular carcinoma (HCC) in community residents in Olmsted County, Minnesota, and their survival. Patients and Methods: Olmsted County residents 20 years or older with HCC newly diagnosed from January 1, 1976, through December 31, 2008, were identified using a community-wide medical record linkage system (Rochester Epidemiology Project). The incidence rate of HCC was calculated by age and sex according to the 2000 US Census population. Temporal trends of HCC etiology, treatment, and patient survival were assessed. Results: The age- and sex-adjusted incidence rate for HCC in Olmsted County was 3.5 per 100,000 person-years for the first era (1976-1990), 3.8 per 100,000 for the second era (1991-2000), and 6.9 per 100,000 for the third era (2001-2008). Alcohol use was the most common risk factor in the first and second eras and chronic hepatitis C virus in the third. The proportion attributed to nonalcoholic fatty liver disease was small (5/47 [10.6%] in the third era). Because the proportion of patients receiving curative treatment increased over time, survival also improved, with a median survival time of 3, 6, and 9 months in the first, second, and third eras, respectively (P=.01). Conclusion: In this midwestern US community, the incidence of HCC has increased, primarily due to hepatitis C virus. Although there was a demonstrable improvement in the outcome of HCC in community residents over time, the overall prognosis remains poor.
UR - http://www.scopus.com/inward/record.url?scp=84862908535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862908535&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2011.07.001
DO - 10.1016/j.mayocp.2011.07.001
M3 - Article
C2 - 22212963
AN - SCOPUS:84862908535
SN - 0025-6196
VL - 87
SP - 9
EP - 16
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 1
ER -